This finding indicated that CTRP9 has great promise in transforming the treatment of diabetes-associated atherosclerosis by improving cardiovascular outcomes independent of glycemic control, which is inconsistent with previous observations. This evidence concerns the gene C1QTNF9 and diabetes mellitus.